Quest Diagnostics Incorporated (DGX) reported $11.84B of revenue for the twelve months ended Sep 30, 2026. That is up 9.1% from the year before. Revenue for fiscal 2025 was $11.04B.

Yes. Quest Diagnostics Incorporated earned $1.13B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.5%.

How much cash and debt does DGX have?

Quest Diagnostics Incorporated reported $797.00M in cash and cash equivalents and $5.55B of debt on its most recent balance sheet in SEC filings.

How fast is DGX revenue growing?

Quest Diagnostics Incorporated's revenue changed +11.8% in fiscal 2025, to $11.04B. Its compound annual growth rate was +3.2% over 5 years and +3.9% over 10 years.

What is DGX gross margin?

Quest Diagnostics Incorporated's gross profit was $3.92B on $11.84B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 33.1%.

What is DGX free cash flow?

Quest Diagnostics Incorporated generated $1.38B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.95B less capital expenditures.

What is DGX earnings per share?

Diluted earnings per share were $10.04 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did DGX last report financial results?

The latest statements here come from Quest Diagnostics Incorporated's 10-Q filed on Oct 23, 2026, covering the period ended Sep 30, 2026.

Financials · DGX

Quest Diagnostics Incorporated (DGX) financials

For the twelve months ended Sep 30, 2026, Quest Diagnostics Incorporated reported $11.84B of revenue and $1.13B of net income.

Revenue, TTM: $11.84B
Revenue growth, YoY: +9.1%
Net income, TTM: $1.13B
Net income growth, YoY: +16.5%
Net margin: 9.5%
Free cash flow, TTM: $1.38B
EPS, diluted, TTM: $10.04
EPS growth, YoY: +17.8%
Cash: $797.00M
Total debt: $5.55B
P/E: 24.91
P/S: 2.38
Market cap: $28.12B

Annual revenue$11.04B

FY2016FY2025

Annual net income$992.00M

FY2016FY2025

Annual free cash flow$1.36B

FY2016FY2025

DGX revenue and earnings growth

DGX revenueQ3 2026$3.10B

Quarter YoY: +10.0%
QoQ: +1.8%
FY YoY: +11.8%
5Y CAGR: +3.2%
10Y CAGR: +3.9%

DGX revenue was $3.10B in fiscal Q3 2026 (ended Sep 30, 2026), up 10.0% from a year earlier and up 1.8% from the prior quarter. For the full fiscal 2025 it was $11.04B, up 11.8% from fiscal 2024. Compound annual growth was +3.2% over 5 years and +3.9% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

DGX net incomeQ3 2026$312.00M

Quarter YoY: +27.3%
QoQ: -2.5%
FY YoY: +13.9%
5Y CAGR: -7.1%
10Y CAGR: +3.4%

DGX net income was $312.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 27.3% from a year earlier and down 2.5% from the prior quarter. For the full fiscal 2025 it was $992.00M, up 13.9% from fiscal 2024. Compound annual growth was -7.1% over 5 years and +3.4% over 10 years. It rose in 6 of the last 10 fiscal years.

DGX EPSQ3 2026$2.78

Quarter YoY: +28.7%
QoQ: -2.1%
FY YoY: +13.8%
5Y CAGR: -3.5%
10Y CAGR: +6.0%

DGX diluted EPS was $2.78 in fiscal Q3 2026 (ended Sep 30, 2026), up 28.7% from a year earlier and down 2.1% from the prior quarter. For the full fiscal 2025 it was $8.75, up 13.8% from fiscal 2024. Compound annual growth was -3.5% over 5 years and +6.0% over 10 years.

DGX free cash flowQ3 2026$445.00M

Quarter YoY: +6.2%
QoQ: -3.1%
FY YoY: +49.5%
5Y CAGR: -3.1%
10Y CAGR: +9.3%

DGX free cash flow was $445.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 6.2% from a year earlier and down 3.1% from the prior quarter. For the full fiscal 2025 it was $1.36B, up 49.5% from fiscal 2024. Compound annual growth was -3.1% over 5 years and +9.3% over 10 years. It rose in 7 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$11.04B	$9.87B	$9.25B	$9.88B	$10.79B	$9.44B	$7.73B	$7.53B	$7.40B	$7.21B
Cost of revenue	$7.37B	$6.63B	$6.20B	$6.45B	$6.58B	$5.80B	$5.04B	$4.93B	$4.72B	$4.62B
Gross profit	$3.67B	$3.24B	$3.05B	$3.43B	$4.21B	$3.63B	$2.69B	$2.60B	$2.68B	$2.90B
Selling, general and admin	$1.97B	$1.77B	$1.64B	$1.87B	$1.73B	$1.55B	$1.46B	$1.42B	$1.44B	$1.38B
Operating income	$1.56B	$1.35B	$1.26B	$1.43B	$2.38B	$1.97B	$1.23B	$1.10B	$1.17B	$1.28B
Interest expense	-	-	$163.00M	$148.00M	$152.00M	$166.00M	$180.00M	$169.00M	$153.00M	$144.00M
Pre-tax income	$1.32B	$1.18B	$1.13B	$1.24B	$2.60B	$1.88B	$1.08B	$926.00M	$1.03B	$1.09B
Income tax	$314.00M	$273.00M	$248.00M	$264.00M	$597.00M	$460.00M	$247.00M	$182.00M	$241.00M	$429.00M
Net income	$992.00M	$871.00M	$854.00M	$946.00M	$2.00B	$1.43B	$858.00M	$736.00M	$772.00M	$645.00M
EPS, basic	$8.87	$7.78	$7.59	$8.10	$15.85	$10.62	$6.36	$5.39	$5.63	$4.58
EPS, diluted	$8.75	$7.69	$7.49	$7.97	$15.55	$10.47	$6.28	$5.29	$5.50	$4.51
Diluted shares	113.0M	113.0M	113.0M	118.0M	128.0M	136.0M	136.0M	139.0M	140.0M	142.0M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$420.00M	$549.00M	$686.00M	$315.00M	$872.00M	$1.16B	$1.19B	$135.00M	$137.00M	$384.00M
Receivables	$1.41B	$1.30B	$1.21B	$1.20B	$1.44B	$1.52B	$1.06B	$1.01B	$924.00M	$926.00M
Inventory	$189.00M	$188.00M	$190.00M	$192.00M	$208.00M	$223.00M	$123.00M	$99.00M	$95.00M	$82.00M
Current assets	$2.38B	$2.39B	$2.37B	$1.90B	$2.74B	$3.06B	$2.49B	$1.39B	$1.31B	$1.53B
Goodwill	$8.95B	$8.86B	$7.73B	$7.22B	$7.09B	$6.87B	$6.62B	$6.56B	$6.33B	$6.00B
Total assets	$16.23B	$16.15B	$14.02B	$12.84B	$13.61B	$14.03B	$12.84B	$11.00B	$10.50B	$10.10B
Current liabilities	$2.28B	$2.17B	$1.81B	$1.55B	$1.75B	$1.78B	$1.99B	$1.49B	$1.06B	$981.00M
Short-term debt	$504.00M	$602.00M	$303.00M	$2.00M	$2.00M	$2.00M	$804.00M	$464.00M	$36.00M	$6.00M
Long-term debt	$5.17B	$5.62B	$4.41B	$3.98B	$4.01B	$4.01B	$3.97B	$3.43B	$3.75B	$3.73B
Total debt	$5.67B	$6.22B	$4.71B	$3.98B	$4.01B	$4.01B	$4.77B	$3.89B	$3.78B	$3.73B
Total liabilities	$9.02B	$9.34B	$7.68B	$6.91B	$7.13B	$7.22B	$7.16B	$5.74B	$5.55B	$5.44B
Shareholders' equity	$7.17B	$6.81B	$6.34B	$5.93B	$6.48B	$6.81B	$5.69B	$5.27B	$4.96B	$4.66B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$1.89B	$1.33B	$1.27B	$1.72B	$2.23B	$2.00B	$1.24B	$1.20B	$1.18B	$1.12B
Capital expenditures	$527.00M	$425.00M	$408.00M	$404.00M	$403.00M	$418.00M	$400.00M	$383.00M	$252.00M	$293.00M
Free cash flow	$1.36B	$909.00M	$864.00M	$1.31B	$1.83B	$1.59B	$843.00M	$817.00M	$923.00M	$823.00M
Investing cash flow	-$631.00M	-$2.55B	-$1.06B	-$543.00M	$21.00M	-$772.00M	-$411.00M	-$801.00M	-$830.00M	-$127.00M
Financing cash flow	-$1.39B	$1.08B	$160.00M	-$1.73B	-$2.54B	-$1.27B	$225.00M	-$401.00M	-$592.00M	-$738.00M
Dividends paid	$353.00M	$331.00M	$314.00M	$305.00M	$309.00M	$297.00M	$286.00M	$266.00M	$247.00M	$223.00M
Share repurchases	$450.00M	$151.00M	$275.00M	$1.41B	$2.20B	$325.00M	$353.00M	$322.00M	$465.00M	$590.00M
Stock-based compensation	$88.00M	$88.00M	$77.00M	$77.00M	$79.00M	$97.00M	$56.00M	$61.00M	$79.00M	$69.00M
Depreciation and amortization	$570.00M	$493.00M	$439.00M	$437.00M	$408.00M	$361.00M	$329.00M	$309.00M	$270.00M	$249.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	11.8%	6.7%	-6.4%	-8.4%	14.3%	22.1%	2.6%	1.7%	2.6%	-3.7%
Net income growth, YoY	13.9%	2.0%	-9.7%	-52.6%	39.4%	66.8%	16.6%	-4.7%	19.7%	-9.0%
EPS growth, YoY	13.8%	2.7%	-6.0%	-48.7%	48.5%	66.7%	18.7%	-3.8%	22.0%	-7.4%
Gross margin	33.2%	32.9%	33.0%	34.7%	39.0%	38.5%	34.8%	34.6%	36.2%	40.2%
Operating margin	14.1%	13.6%	13.6%	14.4%	22.1%	20.9%	15.9%	14.6%	15.7%	17.7%
Net margin	9.0%	8.8%	9.2%	9.6%	18.5%	15.2%	11.1%	9.8%	10.4%	8.9%
Free cash flow margin	12.3%	9.2%	9.3%	13.3%	17.0%	16.8%	10.9%	10.8%	12.5%	11.4%
Return on equity	13.8%	12.8%	13.5%	16.0%	30.8%	21.0%	15.1%	14.0%	15.6%	13.8%
Return on assets	6.1%	5.4%	6.1%	7.4%	14.7%	10.2%	6.7%	6.7%	7.4%	6.4%
Current ratio	1.04	1.10	1.31	1.22	1.56	1.72	1.25	0.94	1.24	1.56
Debt to equity	0.79	0.91	0.74	0.67	0.62	0.59	0.84	0.74	0.76	0.80

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$3.10B	$3.04B	$2.90B	$2.81B	$2.82B	$2.76B	$2.65B	$2.62B	$2.49B	$2.40B	$2.37B	$2.29B
Cost of revenue	$2.06B	$2.02B	$1.95B	$1.90B	$1.87B	$1.82B	$1.79B	$1.76B	$1.68B	$1.59B	$1.59B	$1.55B
Gross profit	$1.04B	$1.03B	$942.00M	$910.00M	$949.00M	$943.00M	$863.00M	$858.00M	$811.00M	$804.00M	$771.00M	$736.00M
Selling, general and admin	$523.00M	$529.00M	$504.00M	$504.00M	$501.00M	$486.00M	$476.00M	$466.00M	$448.00M	$416.00M	$440.00M	$407.00M
Operating income	$479.00M	$459.00M	$399.00M	$386.00M	$386.00M	$438.00M	$346.00M	$361.00M	$330.00M	$355.00M	$300.00M	$267.00M
Interest expense	-	-	-	-	-	-	-	-	-	$47.00M	$49.00M	$46.00M
Pre-tax income	$416.00M	$412.00M	$334.00M	$330.00M	$328.00M	$384.00M	$276.00M	$299.00M	$296.00M	$314.00M	$266.00M	$237.00M
Income tax	$99.00M	$88.00M	$74.00M	$81.00M	$77.00M	$97.00M	$59.00M	$68.00M	$65.00M	$74.00M	$66.00M	$40.00M
Net income	$312.00M	$320.00M	$252.00M	$245.00M	$245.00M	$282.00M	$220.00M	$222.00M	$226.00M	$229.00M	$194.00M	$192.00M
EPS, basic	$2.82	$2.88	$2.27	$2.21	$2.18	$2.51	$1.97	$1.98	$2.01	$2.05	$1.74	$1.72
EPS, diluted	$2.78	$2.84	$2.24	$2.18	$2.16	$2.47	$1.94	$1.95	$1.99	$2.03	$1.72	$1.70
Diluted shares	112.0M	112.0M	112.0M	-	113.0M	113.0M	113.0M	-	113.0M	112.0M	112.0M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$797.00M	$626.00M	$393.00M	$420.00M	$432.00M	$319.00M	$188.00M	$549.00M	$764.00M	$271.00M	$474.00M	$686.00M
Receivables	$1.71B	$1.67B	$1.59B	$1.41B	$1.46B	$1.42B	$1.40B	$1.30B	$1.38B	$1.32B	$1.32B	$1.21B
Inventory	$218.00M	$233.00M	$225.00M	$189.00M	$186.00M	$187.00M	$189.00M	$188.00M	$184.00M	$182.00M	$181.00M	$190.00M
Current assets	$3.12B	$2.84B	$2.57B	$2.38B	$2.41B	$2.20B	$2.08B	$2.39B	$2.62B	$2.02B	$2.23B	$2.37B
Goodwill	$9.11B	$9.11B	$9.12B	$8.95B	$8.90B	$8.88B	$8.85B	$8.86B	$8.61B	$7.88B	$7.83B	$7.73B
Total assets	$17.22B	$16.94B	$16.67B	$16.23B	$16.20B	$15.97B	$15.80B	$16.15B	$16.09B	$13.88B	$13.95B	$14.02B
Current liabilities	$1.83B	$1.79B	$2.18B	$2.28B	$2.13B	$2.02B	$1.44B	$2.17B	$2.09B	$2.01B	$2.30B	$1.81B
Short-term debt	$10.00M	$10.00M	$503.00M	$504.00M	$504.00M	$504.00M	$1.00M	$602.00M	$603.00M	$606.00M	$906.00M	$303.00M
Long-term debt	$5.54B	$5.63B	$5.16B	$5.17B	$5.17B	$5.17B	$5.86B	$5.62B	$5.65B	$3.82B	$3.80B	$4.41B
Total debt	$5.55B	$5.64B	$5.66B	$5.67B	$5.67B	$5.67B	$5.86B	$6.22B	$6.25B	$4.42B	$4.71B	$4.71B
Total liabilities	$9.27B	$9.12B	$9.01B	$9.02B	$8.90B	$8.70B	$8.84B	$9.34B	$9.25B	$7.22B	$7.49B	$7.68B
Shareholders' equity	$7.63B	$7.82B	$7.67B	$7.17B	$7.29B	$7.26B	$6.96B	$6.81B	$6.84B	$6.66B	$6.47B	$6.34B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$611.00M	$597.00M	$278.00M	$465.00M	$563.00M	$544.00M	$314.00M	$464.00M	$356.00M	$360.00M	$154.00M	$527.00M
Capital expenditures	$166.00M	$138.00M	$114.00M	$158.00M	$144.00M	$108.00M	$117.00M	$123.00M	$106.00M	$92.00M	$104.00M	$72.00M
Free cash flow	$445.00M	$459.00M	$164.00M	$307.00M	$419.00M	$436.00M	$197.00M	$341.00M	$250.00M	$268.00M	$50.00M	$455.00M
Investing cash flow	-$169.00M	-$134.00M	-$152.00M	-$191.00M	-$201.00M	-$124.00M	-$115.00M	-$502.00M	-$1.63B	-$200.00M	-$213.00M	-$114.00M
Financing cash flow	-$271.00M	-$229.00M	-$152.00M	-$287.00M	-$247.00M	-$293.00M	-$561.00M	-$170.00M	$1.77B	-$363.00M	-$153.00M	$130.00M
Dividends paid	$95.00M	$96.00M	$88.00M	$90.00M	$89.00M	$90.00M	$84.00M	$84.00M	$84.00M	$84.00M	$79.00M	$80.00M
Share repurchases	$150.00M	-	-	$300.00M	$150.00M	-	-	$151.00M	-	-	-	$275.00M
Stock-based compensation	$20.00M	$23.00M	$20.00M	$25.00M	$20.00M	$21.00M	$22.00M	$27.00M	$19.00M	$20.00M	$22.00M	$19.00M
Depreciation and amortization	$147.00M	$146.00M	$147.00M	$145.00M	$142.00M	$143.00M	$140.00M	$135.00M	$125.00M	$117.00M	$116.00M	$109.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	10.0%	10.2%	9.2%	7.1%	13.2%	15.2%	12.1%	14.6%	8.4%	2.5%	1.5%	-1.9%
Net income growth, YoY	27.3%	13.5%	14.5%	10.4%	8.4%	23.1%	13.4%	15.6%	0.4%	-2.6%	-4.0%	90.1%
EPS growth, YoY	28.7%	15.0%	15.5%	11.8%	8.5%	21.7%	12.8%	14.7%	1.5%	-1.0%	-3.4%	84.8%
Gross margin	33.6%	33.7%	32.5%	32.4%	33.7%	34.2%	32.5%	32.7%	32.6%	33.5%	32.6%	32.2%
Operating margin	15.5%	15.1%	13.8%	13.8%	13.7%	15.9%	13.0%	13.8%	13.3%	14.8%	12.7%	11.7%
Net margin	10.1%	10.5%	8.7%	8.7%	8.7%	10.2%	8.3%	8.5%	9.1%	9.6%	8.2%	8.4%
Free cash flow margin	14.4%	15.1%	5.7%	10.9%	14.9%	15.8%	7.4%	13.0%	10.0%	11.2%	2.1%	19.9%
Current ratio	1.70	1.59	1.18	1.04	1.13	1.09	1.44	1.10	1.25	1.00	0.97	1.31
Debt to equity	0.73	0.72	0.74	0.79	0.78	0.78	0.84	0.91	0.91	0.66	0.73	0.74

Source: XBRL data Quest Diagnostics Incorporated files with the SEC, latest filing dated Oct 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DGX peers

Company	Revenue	Growth	Net income	Net margin	Market cap
DGX	$11.84B	+9.1%	$1.13B	9.5%	$28.12B
UNHUnitedHealth Group Incorporated	$449.66B	+3.3%	$15.88B	3.5%	$353.17B
ELVElevance Health Inc.	$201.83B	+3.6%	$5.13B	2.5%	$91.96B
CIThe Cigna Group	$286.32B	+6.8%	$5.99B	2.1%	$77.58B
HUMHumana Inc.	$137.20B	+14.1%	$1.13B	0.8%	$52.08B
NTRANatera Inc.	$2.91B	+37.4%	-$164.71M	-5.7%	$44.78B
CNCCentene Corporation	$203.90B	+9.7%	$1.46B	0.7%	$34.53B
ILMNIllumina Inc.	$4.54B	+5.8%	$895.00M	19.7%	$32.22B
LHLabcorp Holdings Inc.	$14.59B	+6.0%	$1.00B	6.9%	$29.77B

DGX FAQ

9 questions

What is DGX revenue?
Quest Diagnostics Incorporated (DGX) reported $11.84B of revenue for the twelve months ended Sep 30, 2026. That is up 9.1% from the year before. Revenue for fiscal 2025 was $11.04B.
Is DGX profitable?
Yes. Quest Diagnostics Incorporated earned $1.13B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.5%.
How much cash and debt does DGX have?
Quest Diagnostics Incorporated reported $797.00M in cash and cash equivalents and $5.55B of debt on its most recent balance sheet in SEC filings.
How fast is DGX revenue growing?
Quest Diagnostics Incorporated's revenue changed +11.8% in fiscal 2025, to $11.04B. Its compound annual growth rate was +3.2% over 5 years and +3.9% over 10 years.
What is DGX gross margin?
Quest Diagnostics Incorporated's gross profit was $3.92B on $11.84B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 33.1%.
What is DGX free cash flow?
Quest Diagnostics Incorporated generated $1.38B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.95B less capital expenditures.
What is DGX earnings per share?
Diluted earnings per share were $10.04 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did DGX last report financial results?
The latest statements here come from Quest Diagnostics Incorporated's 10-Q filed on Oct 23, 2026, covering the period ended Sep 30, 2026.
Where does this DGX financial data come from?
Quantisnow builds these statements from the structured XBRL data Quest Diagnostics Incorporated files with the SEC. It is provided for information only and is not investment advice.